A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002

Indolent Systemic Mastocytosis Clinical Trial

Official title:

A Phase 1, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 in Patients With Indolent Systemic Mastocytosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02808793
• Other study ID #: AK002-001
• Status: Completed
• Phase: Phase 1
• Start date: June 2016
• Est. completion date: December 2018

Study information

• Verified date: March 2019
• Source: Allakos, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1 study to investigate the safety and tolerability of AK002 in patients with indolent systemic mastocytosis (ISM).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Provided written informed consent

2. Male or female aged =18 and =65 years at the time of signing the informed consent form

3. Confirmed diagnosis of ISM based on World Health Organization (WHO) criteria (Appendix 1)

4. Presence of at least 1 of the following SM related symptoms:

1. Flushing (at least 1 episode per week)

2. Pruritus (minimum MAS2 score of 4) (Appendix 2)

3. Diarrhea (minimum MAS2 score of 4) (Appendix 2)

4. Anaphylaxis (at least 1 episode [grade 2 or higher] within the last 12 months)

5. Serum total tryptase exceeded 15 ng/mL* at 2 or more measurements obtained 1 or more months apart within the last 2 years (*Note: this varies from the minor criterion of "persistently exceeds 20 ng/mL" in the WHO criteria for diagnosis of ISM)

6. Willing and able to comply with the study procedures and visit schedule, including follow-up visits

7. Able to communicate effectively with the study site personnel

8. Negative Screening urine drug tests (alcohol, amphetamines/methamphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, cotinine, methadone, methaqualone, opiates, phencyclidine)

9. Negative Screening ova and parasite test

10. Determined by the Investigator to be in good health as documented by the medical history, physical examination (PE), vital sign assessments, 12- lead ECG, clinical laboratory assessments, and by general observations

11. Women of child bearing potential, must be using highly effective methods of birth control (failure rate <1% per year when used consistently and correctly) at least 4 weeks prior to Screening until Day 85. Women should be informed of the potential risks associated with becoming pregnant while enrolled. Accepted forms of contraception are implants, injectables, combined oral contraceptives, and some intrauterine devices (IUDs). In addition, a barrier method must always be used concomitantly to the highly effective method. Double-barrier is not considered a highly effective method. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not an acceptable means of contraception. Female patients are considered to not be of child-bearing potential when they are post-menopausal for at least 2 years with follicle-stimulating hormone (FSH) levels >40 mIU/mL, are surgically sterilized, or have undergone hysterectomy.

12. Male patients with female partners of childbearing potential must agree to use a condom without spermicide during sexual activity with female partners of childbearing potential. Female sexual partners of male patients must be willing to avoid pregnancy according to the above described methods.

Exclusion Criteria:

1. Known hypersensitivity to any constituent of the study drug

2. Presence of an associated hematologic non-mast-cell lineage disorder or MC leukemia

3. Any disease or condition (medical or surgical) which, in the opinion of the Investigator, might compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, skeletal, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of AK002, or would place the patient at increased risk

4. The presence of abnormal laboratory values considered to be clinically significant by the Investigator

5. Participation in a concurrent interventional study with the last intervention occurring within 30 days prior to administration of study drug (90 days or 5 half-lives, whichever is longer, for biologic products)

6. Treatment with chemotherapy or radiotherapy in the preceding 6 months

7. Treatment for a clinically significant helminthic parasitic infection within 6 months of screening

8. Use during the 7 days before Screening (or 5 half-lives, whichever is longer) or expected to require the use of angiotensin converting enzyme (ACE) inhibitors or beta blockers

9. Use during the 30 days before Screening (or 5 half lives, whichever is longer) or expected to require the use of omalizumab, immunosuppressive drugs, or systemic corticosteroids with a daily dose >10 mg prednisone or equivalent

10. Vaccination with live attenuated vaccines within 30 days prior to initiation of treatment in the study, during the treatment period, or vaccination expected within 5 half-lives (4 months) of the study drug administration

11. Donation or loss of >500 mL of blood within 56 days prior to administration of study drug or donation of plasma within 7 days prior to administration of study drug

12. Has not refrained from excessive caffeine consumption (>3 cups of coffee per day or equivalent) for 48 hours prior to study drug administration and agreed to this do so throughout the inpatient period

13. Positive hepatitis serology results, except for vaccinated patients or patients with past but resolved hepatitis, at Screening

14. Positive HIV serology results at Screening

15. Any other reason that in the opinion of the Investigator or the Medical Monitor makes the patient unsuitable for enrollment

16. Patient is vulnerable (e.g., patient kept in detention)

Related Conditions & MeSH terms

• Indolent Systemic Mastocytosis
• Mastocytosis

Intervention

Drug:
• AK002

Locations

Country	Name	City	State
Germany	Charité - Universitätsmedizin Berlin	Berlin

Sponsors (1)

Lead Sponsor	Collaborator
Allakos, Inc.

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the safety and tolerability by evaluating Clinical laboratory parameters and adverse events assessed using the CTCAE version 4		From study start to Day 85 or early term visit
Secondary	Evaluate PK of AK002 in patients with ISM		Through out the study from baseline to Day 85 or early term visit
Secondary	Evaluate the change from baseline in absolute peripheral counts of eosinophils and basophils.		Through out the study from screening to Day 85 or early term visit
Secondary	Evaluate the change from baseline in serum tryptase and eosinophil grande protein levels.		Through out the study from screening to Day 29 or early term visit
Secondary	Measure changes form baseline in the 24-hour urine histamine metabolites.		Starting pre dose on day -1 to days 1, 3 and 4
Secondary	Mastocytosis Quality of Life Questionnaire		Through out the study from screening to Day 85 or early term visit